Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients

Chloé Dimeglio; Arnaud Del Bello; Sabine Chapuy-Regaud; Laure Esposito; Chloé Danet; Chloé Couat; Jacques Izopet; Nassim Kamar

doi:10.1097/TP.0000000000004087

Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients

Transplantation. 2022 May 1;106(5):e275-e276. doi: 10.1097/TP.0000000000004087. Epub 2022 Mar 8.

Authors

Chloé Dimeglio^{1

2

3}, Arnaud Del Bello^{2

4}, Sabine Chapuy-Regaud^{1

2

3}, Laure Esposito⁴, Chloé Danet⁵, Chloé Couat⁴, Jacques Izopet^{1

2

3}, Nassim Kamar^{2

3

4}

Affiliations

¹ Laboratory of Virology, Toulouse Purpan University Hospital, Toulouse, France.
² INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, France.
³ Paul Sabatier University, Toulouse, France.
⁴ Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France.
⁵ Department of Pharmacy, Toulouse University Hospital, Toulouse, France.

Abstract

formula image

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19* / prevention & control
Humans
Organ Transplantation* / adverse effects
SARS-CoV-2
Transplant Recipients

Substances

Antibodies, Monoclonal, Humanized
imdevimab
casirivimab